Erythroid Maturation Agent

Anemia

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-9"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">Luspatercept-aamt is an erythroid maturation agent. Luspatercept-aamt is a receptor fusion protein consisting of a modified extracellular domain of the human activin receptor type IIB linked to a human IgG1 Fc domain with a calculated molecular mass of approximately 76 kD. Luspatercept is produced in Chinese hamster ovary cells by recombinant DNA technology. </p><p>REBLOZYL (luspatercept-aamt) for injection is a sterile, preservative-free, white to off-white, lyophilized powder in single-dose vials for subcutaneous use after reconstitution.</p><p>Each 25 mg single-dose vial provides nominal 25 mg of luspatercept-aamt and citric acid monohydrate (0.085 mg), polysorbate 80 (0.10 mg), sucrose (45.0 mg), and tri-sodium citrate dihydrate (1.35 mg) at pH 6.5. After reconstitution with 0.68 mL Sterile Water for Injection USP, the resulting concentration is 25 mg/0.5 mL of luspatercept-aamt and the nominal deliverable volume is 0.5 mL.</p><p>Each 75 mg single-dose vial provides nominal 75 mg of luspatercept-aamt and citric acid monohydrate (0.254 mg), polysorbate 80 (0.30 mg), sucrose (135 mg), and tri-sodium citrate dihydrate (4.06 mg) at pH 6.5. After reconstitution with 1.6 mL Sterile Water for Injection USP, the resulting concentration is 75 mg/1.5 mL (50 mg/mL) of luspatercept-aamt and the nominal deliverable volume is 1.5 mL.</p></section>

Reblozyl

luspatercept-aamt

luspatercept

luspatercept-aamt 25 MG Injection

luspatercept-aamt 25 MG Injection [Reblozyl]

luspatercept-aamt 75 MG Injection

luspatercept-aamt 75 MG Injection [Reblozyl]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event

Prescribing Information

Medication Guide 

Submit MSL Request 

Pharmacy List 

How To Order Reblozyl

Billing & Coding Guide 

Formulary Information 

Reimbursement Information 

Reblozyl Enrollment Form 

Reblozyl Enrollment Form - Spanish 

Coverage Authorization Request 

Coverage Authorization Appeals 

Commercial Claim Denial Appeal/Redetermination Letter

Medically Unlikely Edit (MUE) Appeal Letter

Letter of Medical Necessity 

Other HCP Resources 

Enroll in Patient Savings Program 

Other HCP Resources: MDS-RS

Patient Brochure: MDS-RS

Caregiver Brochure: MDS-RS

About Reblozyl: MDS-RS

Receiving Reblozyl: MDS-RS

Patient Resources: MDS-RS

Reblozyl Treatment Tracker: MDS-RS

Questions To Ask Your Healthcare Team: MDS-RS

Instructions For Use: MDS-RS

Other HCP Resources: β-Thalassemia

Patient Brochure: β-Thalassemia

About Reblozyl: β-Thalassemia

Receiving Reblozyl: β-Thalassemia

Patient Resources: β-Thalassemia

Questions To Ask Your Healthcare Team: β-Thalassemia

Instructions For Use: β-Thalassemia